Early Evaluation of Tumoral Response to Antiangiogenic Therapy by Arterial Spin Labeling Perfusion Magnetic Resonance Imaging and Susceptibility Weighted Imaging in a Patient With Recurrent Glioblastoma Receiving Bevacizumab

Abstract

A 79-year-old man with recurrent glioblastoma was treated with bevacizumab (10 mg/kg) and irinotecan (125 mg/m 2 ) every 2 weeks for 6 months. He did not receive corticosteroids during this period. The patient underwent a multimodal magnetic resonance imaging (MRI) protocol before treatment (D0) and 15, 30, 90, 120, and 180 days after treatment (D15, D30, D90, D120, and D180, respectively). The MRI study was approved by our institutional committee on ethics, and informed consent was obtained from the patient. Before treatment, fluid-attenuated inversion recovery (FLAIR) abnormalities covered almost all of the right hemisphere